Literature DB >> 8911509

Ability to predict biochemical progression using Gleason score and a computer-generated quantitative nuclear grade derived from cancer cell nuclei.

R W Veltri1, M C Miller, A W Partin, D S Coffey, J I Epstein.   

Abstract

OBJECTIVES: To determine the ability to predict prostate cancer progression using shape, size, and chromatin texture nuclear grading features preselected by logistic regression analyses based on expert-selected prostate cancer cell nuclei captured using a computer-assisted image analysis system.
METHODS: One hundred fifteen patients with clinically localized prostate cancer were identified at the Johns Hopkins medical institutions. The mean follow-up period was 10.4 +/- 1.7 years in 70 patients without disease progression, whereas the mean time to progression for the entire group was 3.8 +/- 2.5 years. Using 5-microns Feulgen-stained tissue sections, approximately 150 cancer cell nuclei were selected and captured for each case using a CAS-200 Image Analysis System. Thirty-eight different nuclear morphometric descriptors (NMDs) were calculated for each cell nucleus. The variance of the NMDs for each tumor was examined by univariate and multivariate logistic regression analyses and by Cox survival analyses to assess their ability to predict prostate cancer progression.
RESULTS: Postoperative Gleason scoring was significantly correlated with disease progression (P < 0.00001; sensitivity, 73%; specificity, 84%; receiver operating characteristic curve area under the curve (ROC-AUC), 83%). Using backward stepwise logistic regression at a stringency of P < 0.05, the variances of 11 of the NMDs were found to be multivariately significant for progression prediction (P < 0.00001; sensitivity, 78%; specificity, 83%; ROC-AUC, 86%). A single value, termed the quantitative nuclear grade (QNG), was created from the variances of these, 11 multivariately significant NMDs using the logistic regression function. The QNG and the postoperative Gleason score were combined to create a model for the prediction of progression having a sensitivity of 89%, specificity of 84%, and ROC-AUC of 92%. These two parameters (QNG and Gleason score) clearly separated the patient sample into three statistically distinct risk groups and predicted the time to progression on the basis of Kaplan-Meier survival probability analysis.
CONCLUSIONS: The QNG, combined with the postoperative Gleason score, may assist in the more accurate stratification of patients undergoing radical prostatectomy into low-, moderate-, and high-risk groups for cancer recurrence and may permit the early initiation of adjuvant therapy.

Entities:  

Mesh:

Year:  1996        PMID: 8911509     DOI: 10.1016/S0090-4295(96)00370-6

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  7 in total

Review 1.  Nuclear morphometry, nucleomics and prostate cancer progression.

Authors:  Robert W Veltri; Christhunesa S Christudass; Sumit Isharwal
Journal:  Asian J Androl       Date:  2012-04-16       Impact factor: 3.285

2.  Morphometric sum optical density as a surrogate marker for ploidy status in prostate cancer: an analysis in 180 biopsies using logistic regression and binary recursive partitioning.

Authors:  Girish Venkataraman; Vijayalakshmi Ananthanarayanan; Gladell P Paner; Rui He; Saeedeh Masoom; James Sinacore; Robert C Flanigan; Eva M Wojcik
Journal:  Virchows Arch       Date:  2006-08-03       Impact factor: 4.064

3.  Quantitative DNA methylation analysis of genes coding for kallikrein-related peptidases 6 and 10 as biomarkers for prostate cancer.

Authors:  Ekaterina Olkhov-Mitsel; Theodorus Van der Kwast; Ken J Kron; Hilmi Ozcelik; Laurent Briollais; Christine Massey; Franz Recker; Maciej Kwiatkowski; Neil E Fleshner; Eleftherios P Diamandis; Alexandre R Zlotta; Bharati Bapat
Journal:  Epigenetics       Date:  2012-08-09       Impact factor: 4.528

Review 4.  Structure and function analysis in circulating tumor cells: using nanotechnology to study nuclear size in prostate cancer.

Authors:  Nu Yao; Yu-Jen Jan; Shirley Cheng; Jie-Fu Chen; Leland Wk Chung; Hsian-Rong Tseng; Edwin M Posadas
Journal:  Am J Clin Exp Urol       Date:  2018-04-01

5.  Improved prediction of prostate cancer recurrence through systems pathology.

Authors:  Carlos Cordon-Cardo; Angeliki Kotsianti; David A Verbel; Mikhail Teverovskiy; Paola Capodieci; Stefan Hamann; Yusuf Jeffers; Mark Clayton; Faysal Elkhettabi; Faisal M Khan; Marina Sapir; Valentina Bayer-Zubek; Yevgen Vengrenyuk; Stephen Fogarsi; Olivier Saidi; Victor E Reuter; Howard I Scher; Michael W Kattan; Fernando J Bianco; Thomas M Wheeler; Gustavo E Ayala; Peter T Scardino; Michael J Donovan
Journal:  J Clin Invest       Date:  2007-07       Impact factor: 14.808

6.  Nuclear morphometry, epigenetic changes, and clinical relevance in prostate cancer.

Authors:  Robert W Veltri; Christhunesa S Christudass
Journal:  Adv Exp Med Biol       Date:  2014       Impact factor: 2.622

7.  Effectiveness and cost-effectiveness of prognostic markers in prostate cancer.

Authors:  N W Calvert; A B Morgan; J W F Catto; F C Hamdy; R L Akehurst; P Mouncey; S Paisley
Journal:  Br J Cancer       Date:  2003-01-13       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.